Transdermal Carbidopa/Levodopa Lotion for Dysphagia-Free Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with Parkinson's Disease face challenges with oral medication administration due to dysphagia and gastrointestinal dysfunction, leading to discomfort and potential health risks, and existing alternative therapies have drawbacks such as skin reactions and non-uniform dose delivery.
Innovation Solution
A transdermal delivery system using a bioactive glass and hyaluronic acid formulation to administer carbidopa/levodopa directly through the skin, bypassing the digestive system and maintaining therapeutic concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral medication is administered to Parkinson's patients, then the medication can be easily delivered and absorbed, but patients experience dysphagia and gastrointestinal dysfunction causing discomfort and health risks
Solution Approach 1:
The patent introduces the skin as an intermediary delivery route between the medication and the bloodstream, bypassing the problematic gastrointestinal tract. The transdermal patch serves as a mediator that delivers carbidopa/levodopa directly through the skin, avoiding dysphagia and GI dysfunction while maintaining effective drug delivery.
Solution Approach 2:
The patent transitions from the traditional oral (gastrointestinal) dimension of drug delivery to a transdermal (cutaneous) dimension. This dimensional change allows medication to bypass the problematic GI tract entirely and enter the bloodstream through the skin, resolving the contradiction between ease of administration and avoidance of GI harm.
2Object-affected harmful factors
If existing alternative therapies are used to avoid oral administration, then dysphagia-related discomfort is reduced, but skin reactions and non-uniform dose delivery occur
Solution Approach 1:
The patent modifies the formulation parameters of carbidopa/levodopa to create a stable, controlled-release transdermal preparation. By adjusting the chemical formulation and delivery mechanism, the patent achieves uniform dose delivery through the skin while minimizing skin reactions, thus resolving the reliability issues of previous alternative therapies.
Solution Approach 2:
The patent replaces the problematic mechanical swallowing action with a passive transdermal diffusion mechanism. The medication is delivered through the skin via controlled diffusion and permeation, eliminating the need for dysphagic swallowing while providing reliable, uniform dose delivery through engineered formulation and delivery system design.
3Reliability
If multiple oral doses are administered throughout the day, then effective symptom management is maintained, but patients must ingest hundreds of pills causing significant burden
Solution Approach 1:
The patent combines multiple daily doses into a single transdermal delivery system that provides continuous medication release throughout the day. The transdermal patch merges the function of multiple oral administrations into one application, maintaining effective symptom management while dramatically reducing the burden of taking hundreds of pills.
Solution Approach 2:
The patent implements continuous drug delivery through the transdermal patch, replacing the discontinuous multiple oral doses. The patch provides sustained, continuous release of carbidopa/levodopa across the day, maintaining reliable symptom management while eliminating the repetitive burden of frequent pill ingestion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable, non-invasive, and controlled delivery of carbidopa/levodopa, reducing dysphagia-related discomfort and gastrointestinal issues while maintaining effective symptom management without altering the prescribed dosage regimen.
Implementation Method 1
a hyaluronic acid in an amount effective to transport the one or more doses of carbidopa 25 mg/levodopa 100 mg transdermally at a site of application by a patient
Implementation Method 2
prescribed doses of carbidopa/levodopa to pass into the bloodstream through the skin where it may circulate systemically in the body
Data Source
AI summary
Disclosed is a system and method for a non-oral dopaminergic therapy for patients with Parkinson's disease, the administration thereof having the benefit of no change in risk to the patient. The disclosed therapy is capable of delivering prescribed doses of carbidopa/levodopa through the skin into the bloodstream where it may circulate systemically in the body, bypassing the digestive system and avoiding first-pass metabolism in the liver. The dislosed drug delivery system enables therapeutic dosages of carbidopa/levodopa to reach the target tissue site in a controlled manner while maintaining the concentration in the therapeutic window.